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Abstract:  Activation  of  the  nuclear  hormone  receptor  peroxisome  proliferator-activated 
receptor gamma (PPAR-γ) has been shown to be immunoregulatory in autoimmune diseases 
by inhibiting production of a number of inflammatory mediators. We investigated whether 
PPAR-γ  gene  deletion  in  hematopoietic  cells  would  alter  disease  pathogenesis  in  the 
antiglomerular basement membrane (anti-GBM) mouse model. PPAR-γ  +/+ and PPAR-γ  -/- mice 
were immunized with rabbit antimouse GBM antibodies and lipopolysaccharide and evaluated 
for two weeks. Although both the PPAR-γ  +/+ and PPAR-γ  -/- mice had IgG deposition in the 
glomerulus and showed proteinuria two weeks after injection, glomerular and tubulointerstitial 
disease in PPAR-γ  -/- mice were significantly more severe compared with the PPAR-γ  +/+ animals. 
We observed that the PPAR-γ  -/- mice had decreased CD4+CD25+ regulatory T cells and an 
increased CD8+:CD4+ ratio as compared with the PPAR-γ  +/+ mice, suggesting that PPAR-γ has 
a role in the regulation of T cells. Furthermore, plasma interleukin-6 levels were significantly 
increased in the PPAR-γ  -/- mice at two weeks as compared with the PPAR-γ  +/+ animals. Taken 
together, these studies show that the lack of PPAR-γ expression enhances inflammatory renal 
disease in the anti-GBM antibody-induced glomerulonephritis mouse model and suggests 
targeting PPAR-γ may have therapeutic efficacy.
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Introduction
Antiglomerular basement membrane (anti-GBM) disease is an autoimmune disorder 
that affects the glomeruli of the kidneys.1 In this disease, glomerular capillaries 
become targets of autoantibodies, or anti-GBM antibodies, which are directed against 
an antigen normally present in the GBM and alveolar basement membrane.2 The 
GBM antigen that is responsible for this disease is a component of the alpha-3 chain 
of Type IV collagen. The resulting clinical syndrome encompasses a spectrum rang-
ing from mild or no renal involvement to rapidly progressive glomerulonephritis. 
Most patients have both pulmonary and kidney involvement.3 Clinically, anti-GBM 
disease that induces both glomerulonephritis and pulmonary hemorrhage is termed 
Goodpasture’s syndrome.1
Lupus nephritis is an immune-mediated disease in which T cells, B cells, and innate 
immune cells have been shown to have pathogenic roles. In mouse models of spontane-
ous lupus nephritis, disease takes 6–12 months to manifest, necessitating the develop-
ment of models that will induce lupus-like disease over a quicker timeframe. One such  Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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model to study spontaneous lupus nephritis is the experimental 
anti-GBM mouse.4,5 GBM glomerulonephritis, characterized by 
crescent formation and necrotizing inflammation of the glom-
erular capillary, is the most severe form of glomerulonephritis. 
When given anti-GBM antibodies and inflammatory stimula-
tion, these animals develop glomerular basement nephritis that 
in many ways resembles lupus nephritis and Goodpasture’s 
disease. The studies of spontaneous lupus nephritis in mouse 
models and experimental anti-GBM disease have provided 
valuable insights into the underlying mechanisms of human 
lupus nephritis.4,6
Peroxisome proliferator-activated receptors (PPARs) 
belong to the 48-member superfamily of nuclear receptor 
proteins that function as transcription factors, regulating 
gene expression. PPARs are receptors for endogenous lipid 
molecules and are the molecular targets for drugs against 
Type 2 diabetes.7,8 They represent promising new targets for 
the treatment and prevention of inflammatory and autoim-
mune disorders, such as inflammatory bowel disease and sys-
temic lupus erythematosus.9–11 Treatment with rosiglitazone, 
a pharmacologic agonist for PPAR-γ of the thiazolidinedione 
class of insulin-sensitizing drugs, has therapeutic efficacy: it 
reduces autoantibody production, atherosclerosis, and renal 
injury in lupus nephritis mice, showing reduced glomerular 
scarring and reduced inflammation in the renal cortex.12,13 
There are three known PPARs (α, β, and γ) that each differ 
in their tissue distribution and functional activity.14 PPAR-γ 
is expressed in T and B cells, monocytes/macrophages, den-
dritic cells, and epithelial cells.15,16 There are three isoforms of 
PPAR-γ;17 the first and third are identical when fully translated 
and only differ in their splice variants, whereas the second 
differs from the other isoforms at the N-terminus.18 All three 
isoforms have been identified in adipocytes. Additionally, 
PPAR-γ1 is present in virtually all other tissues, including 
smooth muscle and splenic tissue. PPAR-γ3 is expressed in 
macrophages and in the colon.19
Whole body deletion of PPAR-γ causes embryonic 
lethality, but several conditional knockout mouse models have 
been developed using homozygous floxed PPAR-γ mice that 
result in epithelial and hematopoietic cells lacking PPAR-
γ.20–23 PPAR-γ conditional knockout peritoneal macrophages 
have markedly reduced expression of ABCG1, reduced 
cholesterol efflux, and more atherosclerosis when crossed to 
a proatherogenic mouse model, such as a low-density lipo-
protein receptor knockout.19 In our current studies, we sought 
to determine if the deletion of PPAR-γ from hematopoietic 
cells would result in more severe development of disease in 
the anti-GBM mouse model, given the anti-inflammatory 
and immunomodulatory effects of PPAR-γ expressed in 
immune cells.
Materials and methods
Mice
In this project we used PPAR-γ floxed mice expressing the 
Cre transgene ((PPAR-γ fl/fl; MMTV-Cre+ or PPAR-γ  -/-) 
and PPAR-γ fl/fl; MMTV-Cre- littermate mice (PPAR-γ  +/+). 
These mice undergo premature termination of translation 
due to the enzymatic activity of recombinase in genomic 
DNA on hematopoietic and epithelial cells.20,24,25 We have 
previously used these mice to cause conditional deletion 
of PPAR-γ in mouse models of irritable bowel disease, 
obesity and diabetes, and inflammation-driven colorectal 
cancer.25–28 All experimental procedures were approved 
by the Institutional Animal Care and Use Committee of 
Virginia Polytechnic Institute and State University, and 
met or exceeded requirements of the Public Health Service/
National Institutes of Health and the United Stated Animal 
Welfare Act as amended.
Anti-GBM sera
Anti-GBM serum was provided by John Zhang (Medical 
University of South Carolina, Charleston, SC). Essentially, 
glomeruli from C57BL/6 mice were isolated with a series 
of grading sieves (150, 106, and 63 µm mesh) and sonicated 
for seven minutes. Rabbits were next immunized with glom-
erular sonicates in complete Freund’s adjuvant, followed by 
two injections of antigen in incomplete Freund’s adjuvant 
(2 mg antigen per rabbit per injection), three weeks apart. 
Sera harvested from these rabbits seven weeks after the 
initial injection were tested by direct immunofluorescence 
to demonstrate strong glomerular binding.
Induction of lupus-like disease
Six- to eight-week-old mice were injected with a single dose 
of 100 µg lipopolysaccharide (Sigma-Aldrich, St Louis, 
MO) in phosphate-buffered saline intraperitoneally and 
administered 250 µg anti-GBM sera in phosphate-buffered 
saline intravenously on day 0 to induce disease. At day 14, 
the mice were euthanized and the tissues were collected and 
analyzed for pathology.5
Measurement of proteinuria
As a measure of renal function, urine was collected at days 
0, 7, and 14 and tested for proteinuria by a standard semi-
quantitative test using Bayer Multistix dipsticks (Bayer, 
Fernwald, Germany). Results were graded according to the Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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manufacturer’s instructions as negative, trace (15–20 mg/dL 
of albumin), 1+ (30 mg/dL), 2+ (100 mg/dL), 3+ (300 mg/dL), 
or 4+ (.500 mg/dL).
Cytokine enzyme-linked  
immunosorbent assay
Interleukin-6 (IL-6) levels in the sera were quantified 
by an enzyme-linked immunosorbent assay according 
to the manufacturer’s instructions (R&D Systems Inc., 
Minneapolis, MN, USA).
Flow cytometric analysis
Flow cytometric analysis was performed using various 
combinations of antibodies, including fluorescein isothiocya-
nate (FITC)-conjugated CD44, R-phycoerythrin-conjugated 
CD4, FITC-conjugated CD8, and PerCP-CY5.5-conjugated 
CD25 rat antimouse monoclonal antibodies (BD Pharmingen, 
San Diego, CA). Splenic cells were isolated as previously 
described.29 Briefly, spleen lymphocytes from PPAR-γ +/+ and 
PPAR-γ  -/- mice were aseptically dissociated, treated with 
Tris-ammonium chloride lysis buffer (pH 7.2) to remove 
erythrocytes, washed, and placed in complete medium con-
sisting of 10% heat-inactivated fetal bovine serum, 200 mM 
L-glutamine, 5000 IU/mL penicillin, 5000 µg/mL strepto-
mycin, and 100 × nonessential amino acids. Cell numbers 
were adjusted to 5 × 106 cells/mL, stained with monoclonal 
antibodies or appropriate fluorochrome-tagged isotype antirat 
IgG2a control antibodies, and analyzed on a Coulter Epics 
XL/MXL flow cytometer (Hialeah, FL).
Kidney pathology
As we previously described, renal pathology was assessed 
by a veterinary pathologist who was blinded to the treatment 
groups.30 At day 14, the mice were euthanized for pathologic 
evaluation. At the time of euthanasia, the mice were weighed 
and the kidneys were removed and divided into sections. One 
portion was placed in neutral buffered formalin for subsequent 
embedding in paraffin, sectioning, and hematoxilyn and eosin 
and periodic acid-Schiff staining. Sections were assessed via 
light microscopy for glomerular proliferation, glomerular 
inflammation, glomerular size, number of nuclei per glomeru-
lus, crescents, necrosis, and fibrosis. Each of these parameters 
was graded as 0 (normal), 1 (mild increase in mesangial matrix 
and cellularity), 2 (moderate increase in mesangial matrix and 
cellularity), 3 (focal endocapillary hypercellularity, obliterated 
capillary lumen, and marked thickening of glomerular base-
ment membrane), or 4 (crescent formation, segmental necrosis, 
marked hypercellularity, and hyalinized glomeruli), and an 
overall glomerular score was derived.31 One portion of the 
kidney was frozen in optimal cutting temperature media and cut 
into 5 µm sections and stained with FITC-conjugated antibodies 
(goat antimouse IgG diluted 1:100, Pierce, Rockford, IL).
Statistical analysis
Statistical analysis was performed by Student’s t-test. 
A P value , 0.05 was considered statistically significant.
Results
Rabbit IgG deposition in kidneys after  
anti-GBM antibody injection
Before assessing the impact of PPAR-γ gene deletion on sus-
ceptibility to immune-mediated glomerular basement nephritis, 
we first sought to determine if the kidneys from the PPAR-γ  +/+ 
and PPAR-γ  -/- mice showed similar glomerular staining pat-
terns to anti-GBM treatment. Fourteen days after the induction 
of disease, the anti-GBM antibodies were observed to bind 
exclusively to the glomerular capillary wall in a linear pattern 
(Figure 1). Additionally, the kidneys from both the PPAR-γ  +/+ 
and PPAR-γ  -/- mice showed similar amounts of rabbit anti-
mouse IgG antibodies in their glomeruli.
Determination of proteinuria
Prior to the induction of disease (day 0), both the PPAR-γ  +/+ and 
PPAR-γ  -/- mice showed minimal proteinuria (Figure 2). At day 
14, both the PPAR-γ  +/+ and PPAR-γ  -/- animals had significantly 
greater amounts of proteinuria by dipstick analysis compared 
with the baseline. The differences were not statistically signifi-
cant between the PPAR-γ  +/+ and PPAR-γ  -/- mice at day 14.
Effect of anti-GBM sera on splenic tissue
At day 14, the animals were sacrificed and the spleen weights 
were measured. The spleen weights and spleen to body 
weights were not statistically different between PPAR-γ  +/+ and 
PPAR-γ  -/- mice (0.056 ± 0.14 g versus 0.054 ± 0.014 g for spleen 
and 22.5 ± 2.3 g versus 23.4 ± 3.2 g body weight,   respectively). 
Figure  1  Representative  picture  of  IgG  staining  in  the  glomerulus  at  D14.  Renal 
deposition of anti-GBM antibodies between PPAR-γ  +/+ (right) and PPAR-γ  -/- mice (left).
Abbreviations:  GBM,  glomerular  basement  membrane;  PPAR-γ,  peroxisome 
proliferator-activated receptor gamma. Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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To characterize the splenic phenotype, we isolated the dissoci-
ated splenocytes. There was no difference in total splenocyte 
numbers between the PPAR-γ  +/+ and PPAR-γ  -/- mice (data 
not shown). Next, we assessed the T cell populations by flow 
cytometry. We examined the CD4+:CD8+ ratio, CD4+CD25+ 
(T regulatory cells), and CD4+CD44+ (activated memory T 
cells) due to prior reports showing PPAR-γ expression or activa-
tion modulates T cell profiles by altering the CD4+:CD8+ ratio 
and the T regulatory cell population.32,33 Our results showed 
that there was no difference in the CD4+CD44+ expression 
profiles in PPAR-γ  +/+ mice compared with PPAR-γ  -/- mice. 
Intriguingly, we found that the PPAR-γ -/- mice exhibited a 
significant decrease in the CD4+:CD8+ T cell ratio, as well as 
a decrease in CD4+CD25+ cells compared with the PPAR-γ  +/+ 
mice (Figure 3 and Table 1).
Kidney pathology
Both PPAR-γ  +/+ and PPAR-γ  -/- mice developed renal dis-
ease with anti-GBM antibody administration characterized 
by relatively mild glomerular inflammation. However, the 
PPAR-γ  -/- mice showed significantly more severe disease 
compared with the PPAR-γ  +/+ mice (Figure 4). In addition to 
increased glomerular inflammation, the PPAR-γ  -/- mice had 
increased mesangial matrix that obliterated the glomerular 
architecture (as shown in the periodic acid-Schiff-stained 
sections of the kidney). Furthermore, several of the PPAR-γ  -/- 
mice showed severe interstitial abnormalities.
Evaluation of cytokine levels
We measured serum levels of the proinflammatory cytokine 
IL-6 as a measure of inflammation (Figure 5). Prior to induc-
tion of anti-GBM disease, IL-6 levels were not detectable. 
Two weeks after anti-GBM antibody administration, IL-6 
levels in the PPAR-γ  -/- mice were significantly elevated 
compared with PPAR-γ  +/+ mice.
Discussion
The activation of PPAR-γ was originally shown to block 
the proinflammatory effects of lipopolysaccharide and 
various cytokines in both monocytes and macrophages by 
antagonizing the activities of AP-1, STAT, and NF-κB.34,35 
Specifically, activation of PPAR-γ decreased the production 
of nitric oxide, IL-6, and tumor necrosis factor-alpha. Since 
these initial observations, numerous studies have further 
characterized the expression, regulation, and mechanism of 
PPAR-γ’s anti-inflammatory activity.
In our current studies, we sought to determine the effects 
of PPAR-γ gene deletion in hematopoietic and epithelial 
cells using a mouse model of induced glomerulonephritis. 
The administration of anti-GBM antibodies and lipopolysac-
charide stimulation serves as an acceptable model for murine 
glomerulonephritis with characteristics of Goodpasture’s 
syndrome as well as lupus nephritis.4,36 Our studies demon-
strate that PPAR-γ has a role in the maintenance of regula-
tory T cell numbers. We found that PPAR-γ gene deletion 
resulted in a decreased CD4+CD25+ T cell population, along 
with an increase in disease in mice challenged with lipopoly-
saccharide and anti-GBM antibodies. This coincides with 
previous reports demonstrating that the deletion of PPAR-γ 
in T regulatory cells abrogates their ability to prevent CD4+ 
T cell-induced colitis in adoptive transfer studies and amelio-
rate graft versus host disease.26,33 We have previously shown 
the importance of T regulatory cells in decreasing disease 
severity in lupus mice.37 Together, these studies indicate 
that a decrease in T regulatory cell numbers and/or function 
contributes to the development of autoimmune diseases.
Several lines of evidence suggest that PPAR-γ exerts 
anti-inflammatory effects by negatively regulating the expres-
sion of proinflammatory genes induced during macrophage 
differentiation/activation and the production of proinflam-
matory cytokines.38 We observed a significant increase in the 
production of Th1/Th17 cytokine IL-6 after PPAR-γ gene 
deletion. IL-6 is not only important for the differentiation of 
Th1/Th17 phenotypes, but is also critical for inhibiting the 
differentiation of T regulatory cells.39 This is consistent with 
our flow cytometry analyses showing a decreased T regula-
tory cell population of mice deficient in PPAR-γ. The general 
skewing of immune cell phenotypes may play a significant 
role during the pathogenesis of renal nephritis and lupus in 
mice and humans. Moreover, the deletion of PPAR-γ in CD4+ 
T cells results in enhanced antigen-specific proliferation and 
overproduction of interferon-γ in response to IL-12, indicat-
ing that adequate expression of PPAR-γ in CD4+ T cells is 
required to downregulate excessive Th1 responses.26
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D
i
p
s
t
i
c
k
 
s
c
o
r
e PPAR-γ+/+
PPAR-γ–/–
0
0
2
T
1
2
3
Figure 2 Proteinuria measured by dipstick analysis in PPAR-γ  +/+ and PPAR-γ  -/- mice. 
There was no significant difference between the groups (n = 10).
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Table 1 Percentage of T cell markers in the spleens of mice with autoimmune anti-GBM glomerulonephritis (n = 10)
Parameter CD4+ T cells CD8+ T cells CD8+:CD4+ ratio CD4+CD44+ cells  CD4+CD25+ cells
PPAR-γ+/+ 13.95 ± 0.4+ 15.86 ± 2.6 1.16 ± 0.08 17.62 ± 2.8 2.84 ± 0.31
PPAR-γ-/- 10.98 ± 0.3 14.95 ± 2.4 1.36 ± 0.13* 17.17 ± 3.4 1.96 ± 0.28*
*P , 0.05.
Abbreviations: GBM, glomerular basement membrane; PPAR-γ, peroxisome proliferator-activated receptor gamma.
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Figure 3 Representative histograms of flow cytometric staining of freshly isolated splenocytes from PPAR-γ  +/+ and PPAR-γ  -/- mice 14 days after stimulation with anti-GBM 
sera/LPS administration. 
Abbreviations: GBM, glomerular basement membrane; PPAR-γ, peroxisome proliferator-activated receptor gamma; LPS, lipopolysaccharide.
Perhaps the most striking difference we observed in the 
PPAR-γ  -/- mice was the more severe development of glom-
erular and interstitial lesions compared with the PPAR-γ  +/+ 
mice, demonstrating the role for PPAR-γ gene expression in 
modulating renal disease. Direct binding of antiglomerular 
antibodies to glomerular antigens plays a key role in disease 
pathogenesis in the GBM model. All specimens of the anti-
GBM antibody-treated mice showed linear deposition of IgG 
along the GBM accompanied by complement C3 deposits. 
Our observations by light microscopy revealed a significant 
overall increase in glomerular pathology, including crescent 
formation in the PPAR-γ  -/- mice, while the PPAR-γ  +/+ mice 
showed less pathology. Interestingly, we found that protei-
nuria was similar in both the PPAR-γ  -/- and PPAR-γ  +/+ mice.  Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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This finding could be due to the single time point at which 
we collected urine and our method of determination of pro-
teinuria. A 24-hour urine collection may have shown a better 
representation of urine output with respect to proteinuria.
In lupus nephritis mouse models, PPAR-γ activation 
has shown therapeutic effects, leading to the reduction of 
disease. Recently Venegas-Pont et al reported that PPAR-γ 
agonists showed beneficial effects on renal function in the 
NZB/W lupus mouse.12 Others have suggested that PPAR-γ 
modulates renal disease in lupus nephritis through induc-
tion of adiponectin.13 These studies support our findings for 
a therapeutic benefit of PPAR-γ in autoimmune nephritis. 
We have previously demonstrated that mesangial cells pro-
duce endogenous PPAR-γ ligands.40 The results presented in 
this paper are in line with the effect of endogenous PPAR-γ 
ligands on PPAR-γ expressed in immune cells, because the 
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Figure 4 Renal pathology of PPAR-γ  +/+ and PPAR-γ  -/- two weeks after anti-GBM administration. A Representative photomicrograph of a kidney from a PPAR-γ  +/+ (upper 
left) and PPAR-γ  -/- (upper right) with hematoxylin and eosin stain (insert 25 × magnification of glomeruli). Note the severe cellular infiltrate and crescent formation in the 
PPAR-γ  -/- mouse kidney. Representative photomicrograph of a kidney from a PPAR-γ  +/+ (lower left) and PPAR-γ  -/- (lower right) with periodic acid-Schiff stain. Note the 
increased deposition of periodic acid-Schiff-positive mesangial matrix in the PPAR-γ  -/- mouse kidney. B Tabulation of renal tubular and C glomerular interstitium. 
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deletion of PPAR-γ resulted in increased kidney pathology 
in autoimmune mice. Additionally, endogenously gener-
ated lipid molecules can also activate PPAR-γ, suggesting 
pharmacologic or dietary intervention may not be required 
for PPAR-γ modulation of disease.41,42 Taken together, these 
observations support a critical role for PPAR-γ expression 
in the maintenance of kidney homeostasis and support the 
notion that PPAR-γ may be a therapeutic avenue to target   
for inhibition of autoimmune inflammatory kidney diseases.
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